Download Files:
Bemnifosbuvir
$142 – $1,650
Products Details
Product Description
– Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity[1][2][3].
Web ID
– HY-137958A
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C24H33FN7O7P
References
– [1]Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104.|[2]Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20.|[3]Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63(12):e01201-19.
CAS Number
– 1998705-64-8
Molecular Weight
– 581.53
Compound Purity
– 99.81
SMILES
– O[C@H]1[C@](F)(C)[C@H](N2C3=NC(N)=NC(NC)=C3N=C2)O[C@@H]1CO[P@](OC4=CC=CC=C4)(N[C@@H](C)C(OC(C)C)=O)=O
Clinical Information
– Phase 3
Research Area
– Infection
Solubility
– DMSO : 200 mg/mL (ultrasonic)
Target
– HCV;SARS-CoV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
